Is AMGEN INC (AMGN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 27.4% / 30% | 4.6% / 30% | 4.8% / 30% | 7.21% / 5% | ✗ NOT HALAL |
| DJIM | 27.4% / 33% | 4.6% / 33% | 4.8% / 33% | 7.21% / 5% | ✗ NOT HALAL |
| MSCI | 60.3% / 33% | 10.1% / 33% | 10.6% / 33% | 7.21% / 5% | ✗ NOT HALAL |
| S&P | 27.4% / 33% | 4.6% / 33% | 4.8% / 33% | 7.21% / 5% | ✗ NOT HALAL |
| FTSE | 60.3% / 33% | 10.1% / 33% | 10.6% / 50% | 7.21% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 70.8% | |
| Operating Margin | 30.5% | |
| Net Margin | 21.0% | |
| Return on Equity (ROE) | 106.1% | |
| Return on Assets (ROA) | 7.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $10.0B |
| Free Cash Flow | $8.1B |
| Total Debt | $54.6B |
| Debt-to-Equity | 640.3 |
| Current Ratio | 1.1 |
| Total Assets | $90.6B |
Price & Trading
| Last Close | $353.16 |
| 50-Day MA | $361.80 |
| 200-Day MA | $318.11 |
| Avg Volume | 2.7M |
| Beta | 0.4 |
|
52-Week Range
$261.43
| |
About AMGEN INC (AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is AMGEN INC (AMGN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), AMGEN INC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is AMGEN INC's debt ratio?
AMGEN INC's debt ratio is 27.4% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 60.3%.
What are AMGEN INC's key financial metrics?
AMGEN INC has a market capitalization of $188.0B, trailing P/E ratio of 24.5, and revenue of $36.8B. The company maintains a gross margin of 70.8% and a net margin of 21.0%. Return on equity stands at 106.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.